北京若生智能科技有限公司
Drug Database
FI

filgrastim (long-acting)

✓ Approved

Win Medica · CSF3R · 重组蛋白

什么是 filgrastim (long-acting)？

filgrastim (long-acting) 是一种重组蛋白，由Win Medica研发。该药已获批，用于治疗相关适应症，给药途径：Unknown。

药物档案

公司Win Medica
药物类别重组蛋白
分子靶点CSF3R
给药途径Unknown
状态Approved
来源： ClinicalTrials.gov, Win Medica

作用机制

分子靶点

filgrastim (long-acting) 作用于 1 个分子靶点：

CSF3Rcolony stimulating factor 3 receptor (CD114, GCSFR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

filgrastim (long-acting) 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Blood and lymphatic system disordersBone marrow disorder✓ Approved

相关研究文献

PubMedAIDS care2026-09-11

Determinants of HIV interruption in treatment in Murang'a County, Kenya: a sequential explanatory mixed-methods study.

Njiru Moses Muriithi MM, Ndege Samson S, Owiny Maurice M, Diero Lameck L et al.

Globally, approximately one-in-four people living with HIV (PLHIV) experiences interruption in treatment (IIT), risking viral rebound, transmission, morbidity, and mortality. Murang'a County reported 82% viral suppression coverage, below Kenya's 94%. This study assessed IIT magnitude and determinants using sequential-explanatory mixed methods across nine high-volume facilities (Jan 2023-Jun 2024). PLHIV missing clinical appointments by >30 days were compared with those retained using descriptive statistics, chi-square, and logistic regression. Among 11,472 PLHIV, 6.5% (742) experienced IIT; 50.8% (377) did not return to care. IIT was associated with age 20-24 (aRR =2.02), 25-49 years (aRR = 2.27), male (aRR = 1.42), viral non-suppression (aRR = 6.35), invalid viral load (aRR = 9.59), ART duration 6-12 months (aRR = 4.96), and WHO stages 3&4 (aRR = 2.08) (All p < 0.001). Focus group discussions revealed HIV undetectable VL equals untransmittable knowledge gaps, negative service experiences, transport costs, long waits, frequent clinic visits, pill burden, stigma, and prayers replacing ART barriers. PLHIV with IIT experienced prolonged care disengagement, with higher rates among younger PLHIV, men, those with unsuppressed and older VL, early ART, and advanced HIV disease, influenced by individual, healthcare systems, treatment-related, and sociocultural barriers. Strengthening early tracing, differentiated service delivery, longer-acting ART, VL monitoring adherence, HIV literacy, and stigma reduction is critical to improving retention.

PMID 42723425
阅读全文 →
PubMedCardiovascular therapeutics2026-09-11

FTH1 mRNA-Protein Discordance in Cardiac Ferroptosis: Multilayer Posttranscriptional and Degradative Control.

Zhou Feng F, Zhou Jia-Bin JB, Yan Yi-Qing YQ, Wei Tian-Peng TP et al.

Ferritin heavy Chain 1 (FTH1) is a key protective factor against ferroptosis in the heart, yet its protein abundance can diverge from transcript levels in cardiac ferroptosis contexts. Since resistance to ferroptosis depends on FTH1 protein abundance rather than transcript levels and its ferroxidase activity cannot be readily compensated by other ferritin subunits, this mismatch is functionally consequential. This review organizes the evidence into three regulatory layers acting downstream of transcription. Iron regulatory protein/iron-responsive element (IRP/IRE) signaling gates ribosome recruitment at the 5 '-untranslated region before translation begins. Epitranscriptomic marks and RNA-binding proteins (RBPs) then route the transcript toward decay or translation, with the N6-methyladenosine (m6A) reader YTHDF2 acting in opposite directions across cardiac contexts. Finally, nuclear receptor Coactivator 4 (NCOA4) delivers assembled ferritin for lysosomal degradation, depleting FTH1 protein independently of transcript level. Together, these mechanisms provide an integrated framework for understanding the mRNA-protein discordance of FTH1 and its contribution to cardiac ferroptosis susceptibility. We also discuss how this framework may inform layer-specific therapeutic strategies and identify the measurements that are missing (labile iron pool, ferritin iron loading, and ferritinophagic flux) before mechanistic insight can translate into clinical cardioprotection.

PMID 42723477
阅读全文 →
PubMedFrontiers in cell and developmental biology2026-09-11

Exosomes: emerging biomarkers and therapeutic potential in postoperative delirium and postoperative cognitive dysfunction.

Li Xinyu X, Xu Li L, Song Qiong Q, Chu Qinjun Q

Postoperative delirium (POD) and postoperative cognitive dysfunction (POCD) are common and clinically significant perioperative neurocognitive disorders that disproportionately affect elderly surgical patients. Despite their substantial impact on postoperative recovery and long-term outcomes, the lack of validated biomarkers and effective targeted therapies remains a major challenge in perioperative medicine. Owing to their intrinsic ability to cross the blood-brain barrier and stably encapsulate central nervous system-derived biomolecules, exosomes have emerged as promising candidates for non-invasive biomarker discovery in POD and POCD. Disease-associated alterations in exosomal cargo, encompassing proteins such as P-tau and Aβ1-42, nucleic acids including miR-584-5p and circRNA_089763, and lipid-associated constituents, provide valuable molecular signatures for early diagnosis, disease stratification, prognostic assessment, and dynamic monitoring of perioperative neurocognitive disorders. It should be noted, however,that the majority of current evidence is extrapolated from Alzheimer's disease and other neurodegenerative conditions rather than directly validated in POD and POCD cohorts, and dedicated prospective studies remain warranted. Exosomes exert therapeutic effects through two complementary mechanisms: serving as vehicles for targeted drug delivery and acting as endogenous neuroprotective mediators. Their excellent biocompatibility,low immunogenicity, and inherent capacity to traverse the blood-brain barrier render them attractive platforms for attenuating neuroinflammation, promoting synaptic repair, enhancing neurogenesis, and restoring blood-brain barrier integrity. Despite their considerable promise, several challenges continue to impede clinical translation, including limitations in large-scale production, the lack of standardized isolation and characterization protocols, biological heterogeneity, and regulatory barriers. Future research should focus on establishing POD/POCD-specific exosomal biomarker panels, developing GMP-compliant manufacturing systems, engineering precision-targeted exosomal therapeutics, and conducting rigorous multicenter clinical studies to validate their safety and efficacy. Exosomes hold substantial promise for transforming the diagnosis and treatment of POD and POCD. With continued advances in engineering technologies, mechanistic understanding, and clinical validation, exosome-based diagnostic and therapeutic strategies are expected to become an integral component of precision perioperative medicine.

PMID 42724471
阅读全文 →
PubMedAmerican journal of cancer research2026-09-11

Pathological role of deubiquitinating enzymes in lung cancer: recent insights and advances.

Huang Qin Q, Zhang Zhen Z, Wang Ya-Ning YN, Li Miao-Miao MM et al.

Lung cancer remains the leading cause of cancer-related death worldwide. Following extensive investigations into the mechanisms of lung cancer and targeted therapy, clinical treatment options are now more abundant than ever. However, the overall rates of treatment success and long-term survival remain low among patients with lung cancer, and the prognosis is even poorer for patients with metastatic disease. In this context, a more comprehensive review of the targeted regulatory mechanisms involved in the occurrence and progression of lung cancer could expand the population of patients benefiting from existing clinical treatments and ultimately improve the prognosis of this malignancy. Deubiquitinating enzymes (DUBs) are a specialized class of cellular proteases. These enzymes cleave ubiquitin moieties from substrate proteins or ubiquitin chains, thereby modulating ubiquitination dynamics. Through this catalytic process, DUBs maintain the dynamic balance of ubiquitination within cells. In recent years, accumulating evidence has demonstrated that DUBs serve diverse regulatory functions in multiple molecular events associated with tumorigenesis and malignant progression. Rather than acting through a single mechanism, DUBs participate in tumor progression through multifaceted pathways. In this comprehensive review, we systematically summarize the recent advances in our understanding of the biological functions of DUBs during the pathogenesis and progression of lung cancer. We highlight the mechanistic roles of various DUBs in tumor initiation, development, and metastasis. The topics covered include the regulation of cancer-associated signaling pathways by DUBs, their role in metabolic reprogramming, the DUB-induced modulation of tumor immune responses, the control of cell cycle progression and proliferation by DUBs, as well as other fundamental cellular processes modulated by these enzymes. In addition, we clarify the pathological mechanisms linking DUBs with lung cancer, including upstream regulators and the corresponding downstream molecular signals. Furthermore, we assess the therapeutic potential of these DUBs as candidate therapeutic targets and mediators of drug resistance. This synthesis of the literature provides a strategic framework for identifying clinically relevant DUB targets in lung cancer.

PMID 42724680
阅读全文 →
PubMedBMJ public health2026-09-11

Evaluating the impact of remote care in sexual and reproductive health services on outcomes and health inequalities in the UK: a retrospective observational study of routine service-level data.

Stirrup Oliver O, Gallego Marquez Nuria N, Tostevin Anna A, Josh Jo J et al.

Remote clinical consultations and online postal self-sampling are increasingly established components of sexual and reproductive healthcare provision in the UK. However, there are concerns that uptake and outcomes of remote healthcare may differ by demographic groups and so increase health inequalities. We conducted a retrospective analysis of service-level data within two case study areas (CSAs) in England and one in Wales. Primary outcomes were treatment within 6 weeks among chlamydia cases and uptake of long-acting reversible contraception (LARC) among women attending for contraceptive care. Outcomes were compared between 2019 and 2022, during which remote care use increased in all CSAs. We evaluated overall change within each CSA, and whether changes differed by age, gender and sexual behaviour, ethnicity and Index of Multiple Deprivation (IMD). Analyses included 446 819 individuals across 2019-2022. Comparing 2019 to 2022, there was a small reduction in chlamydia treatment success in CSA-A (relative risk (RR) 0.95, 95% CI 0.93 to 0.98) and small increases in CSA-B (1.12, 1.10 to 1.14) and CSA-C (1.07, 1.03 to 1.12). Changes did not significantly vary by ethnicity or IMD, but treatment success dropped for men who have sex exclusively with women in CSA-A (RR 0.88 vs 0.98 in women) and increased for 16-34 year-olds in CSA-B (p=0.001 across groups). LARC uptake decreased in CSA-A (RR 0.58, 95% CI 0.55 to 0.60) but increased in CSA-B (1.18, 1.15 to 1.21) and CSA-C (1.06, 1.01 to 1.11) as proportion of contraceptive care episodes, although total LARC fittings fell in all CSAs; reduction was greater in women aged 35-49 in CSA-A (p<0.001) and increase was greater in women 16-34 in CSA-B (p<0.001). There was limited evidence for differences by ethnicity or IMD. The study areas varied in their implementation of remote care and healthcare outcomes, but we found no strong evidence that changes in provision of remote care were associated with increases in health inequity.

PMID 42724725
阅读全文 →
PubMedClinical and experimental hepatology2026-09-11

Treatment of hepatitis C in children and adolescents: our experience to date, current status, and prospects.

Pokorska-Śpiewak Maria M, Talarek Ewa E, Aniszewska Małgorzata M, Dobrzeniecka Anna A et al.

The objective of this review was to summarize previous Polish experience in treating hepatitis C virus (HCV) in children with direct-acting antivirals (DAAs) and to describe the current situation and perspectives for future HCV treatment in the pediatric cohort. Children aged at least 3 years were only included in the national Polish therapeutic HCV program on April 1, 2025. However, since 2018, over 200 children and adolescents have been treated with DAAs in noncommercial and commercial trials and real-life programs. Through the current therapeutic program, only adult dosages and formulations of DAAs are available; thus, younger children may not be included. They may, however, receive pediatric formulations donated courtesy of pharmaceutical companies. Screening programs, at least for children at risk of HCV infection, should be implemented to identify candidates for DAA treatment.

PMID 42724535
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多filgrastim (long-acting)